Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Edelmann F, et al. Among authors: wachter r. Eur J Heart Fail. 2010 Aug;12(8):874-82. doi: 10.1093/eurjhf/hfq087. Epub 2010 Jun 10. Eur J Heart Fail. 2010. PMID: 20538867 Free article. Clinical Trial.
Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction.
Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Düngen HD, Pilz S, Binder L, Stahrenberg R, Schmidt A, März W, Pieske B. Edelmann F, et al. Among authors: wachter r. Eur Heart J. 2012 Jan;33(2):203-12. doi: 10.1093/eurheartj/ehr292. Epub 2011 Aug 19. Eur Heart J. 2012. PMID: 21856682 Clinical Trial.
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-DHF Investigators. Edelmann F, et al. Among authors: wachter r. JAMA. 2013 Feb 27;309(8):781-91. doi: 10.1001/jama.2013.905. JAMA. 2013. PMID: 23443441 Clinical Trial.
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F, Gelbrich G, Duvinage A, Stahrenberg R, Behrens A, Prettin C, Kraigher-Krainer E, Schmidt AG, Düngen HD, Kamke W, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Edelmann F, et al. Among authors: wachter r. Int J Cardiol. 2013 Nov 30;169(6):408-17. doi: 10.1016/j.ijcard.2013.10.018. Epub 2013 Oct 11. Int J Cardiol. 2013. PMID: 24182675 Free article. Clinical Trial.
RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.
Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. Maier LS, et al. Among authors: wachter r. JACC Heart Fail. 2013 Apr;1(2):115-22. doi: 10.1016/j.jchf.2012.12.002. Epub 2013 Apr 1. JACC Heart Fail. 2013. PMID: 24621836 Free article. Clinical Trial.
Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM. Edelmann F, et al. Among authors: wachter r. Eur J Heart Fail. 2015 Feb;17(2):214-23. doi: 10.1002/ejhf.203. Epub 2014 Nov 24. Eur J Heart Fail. 2015. PMID: 25418979 Free article. Clinical Trial.
786 results